Fesoterodine

Drug Profile

Fesoterodine

Alternative Names: 5 hydroxymethyl tolterodine; Fesosterodine; Fesoterodine fumarate; PF-00695838; SPM 007; SPM 907; Toviaz

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Schwarz Pharma
  • Developer Pfizer
  • Class Antispasmodics; Benzhydryl compounds; Esters; Propionic acids; Small molecules; Urologics
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • No development reported Stress incontinence

Most Recent Events

  • 21 Jul 2016 Biomarkers information updated
  • 01 Jun 2015 Pfizer initiates enrolment in a phase III trial for Overactive bladder (In children, In adolescents) in Japan (NCT02501928)
  • 16 Mar 2015 Phase-III development for Overactive bladder (In children and adolescents) is ongoing in USA, Japan, Belgium, Canada, Estonia, Finland, France, Greece, India, Italy, South Korea, Malaysia, Netherlands, Poland, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top